• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Mersana Therapeutics Inc.

    12/23/24 7:50:22 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRSN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)*


    Mersana Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    59045L106

    (CUSIP Number)


    12/19/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    59045L106


    1Names of Reporting Persons

    EcoR1 Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    11,578,447.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    11,578,447.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,578,447.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Percentage calculated based on (a) 11,328,000 shares of Common Stock beneficially owned by the reporting person, plus 8,036,688 shares of Common Stock underlying pre-funded warrants beneficially owned by the reporting person, which warrants are subject to a 9.99% beneficial ownership limitation, and (b) 115,649,928 shares of Common Stock outstanding on December 20, 2024, as reported in the Form 8-K filed by the Issuer on December 20, 2024.


    SCHEDULE 13G

    CUSIP No.
    59045L106


    1Names of Reporting Persons

    Oleg Nodelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    11,578,447.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    11,578,447.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,578,447.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  Percentage calculated based on (a) 11,328,000 shares of Common Stock beneficially owned by the reporting person, plus 8,036,688 shares of Common Stock underlying pre-funded warrants beneficially owned by the reporting person, which warrants are subject to a 9.99% beneficial ownership limitation, and (b) 115,649,928 shares of Common Stock outstanding on December 20, 2024, as reported in the Form 8-K filed by the Issuer on December 20, 2024.


    SCHEDULE 13G

    CUSIP No.
    59045L106


    1Names of Reporting Persons

    EcoR1 Capital Fund Qualified, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,918,474.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,918,474.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,918,474.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.4 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Percentage calculated based on (a) 10,682,303 shares of Common Stock beneficially owned by the reporting person, plus 7,578,596 shares of Common Stock underlying pre-funded warrants beneficially owned by the reporting person, which warrants are subject to a 9.99% beneficial ownership limitation, and (b) 115,649,928 shares of Common Stock outstanding on December 20, 2024, as reported in the Form 8-K filed by the Issuer on December 20, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Mersana Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    840 Memorial Drive, Cambridge, MA 02139
    Item 2. 
    (a)Name of person filing:

    EcoR1 Capital, LLC, a Delaware limited liability company ("EcoR1") EcoR1 Capital Fund Qualified, L.P., a Delaware limited partnership ("Qualified Fund") Oleg Nodelman Qualified Fund is filing this statement jointly with the other reporting persons, but not as a member of a group, and it expressly disclaims membership in a group. In addition, the filing of this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any securities covered by this Schedule 13G. Each reporting person also disclaims beneficial ownership of the securities reported herein except to the extent of that person's pecuniary interest therein.
    (b)Address or principal business office or, if none, residence:

    357 Tehama Street #3 San Francisco, CA 94103
    (c)Citizenship:

    See Item 4 of the cover sheet for each reporting person.
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    59045L106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    EcoR1: 11,578,447 Qualified Fund: 10,918,474 Oleg Nodelman: 11,578,447
    (b)Percent of class:

    EcoR1: 9.99% Qualified Fund: 9.4% Oleg Nodelman: 9.99%  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    EcoR1: 0 Qualified Fund: 0 Oleg Nodelman: 0

     (ii) Shared power to vote or to direct the vote:

    EcoR1: 11,578,447 Qualified Fund: 10,918,474 Oleg Nodelman: 11,578,447

     (iii) Sole power to dispose or to direct the disposition of:

    EcoR1: 0 Qualified Fund: 0 Oleg Nodelman: 0

     (iv) Shared power to dispose or to direct the disposition of:

    EcoR1: 11,578,447 Qualified Fund: 10,918,474 Oleg Nodelman: 11,578,447

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    EcoR1 Capital, LLC
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager
    Date:12/23/2024
     
    Oleg Nodelman
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Reporting person
    Date:12/23/2024
     
    EcoR1 Capital Fund Qualified, L.P.
     
    Signature:/s/ Oleg Nodelman
    Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
    Date:12/23/2024
    Get the next $MRSN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRSN

    DatePrice TargetRatingAnalyst
    2/6/2025Outperform
    William Blair
    11/15/2024$5.00Buy
    Citigroup
    3/19/2024$5.00Underweight → Neutral
    JP Morgan
    2/29/2024$6.00Neutral → Buy
    BTIG Research
    2/29/2024$7.00Neutral → Buy
    Guggenheim
    2/29/2024$2.00 → $7.00Neutral → Outperform
    Wedbush
    12/4/2023$1.00 → $5.00Neutral → Buy
    Citigroup
    7/28/2023$7.00 → $1.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $MRSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hack Andrew A. F. closing all direct ownership in the company (SEC Form 4)

    4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

    1/6/26 6:32:59 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hege Kristen closing all direct ownership in the company (SEC Form 4)

    4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

    1/6/26 4:55:45 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Diaz Allene M. closing all direct ownership in the company (SEC Form 4)

    4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

    1/6/26 4:54:24 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Mersana Therapeutics

    William Blair initiated coverage of Mersana Therapeutics with a rating of Outperform

    2/6/25 7:08:59 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup resumed coverage on Mersana Therapeutics with a new price target

    Citigroup resumed coverage of Mersana Therapeutics with a rating of Buy and set a new price target of $5.00

    11/15/24 8:15:56 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics upgraded by JP Morgan with a new price target

    JP Morgan upgraded Mersana Therapeutics from Underweight to Neutral and set a new price target of $5.00

    3/19/24 7:51:31 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Day One Completes Acquisition of Mersana Therapeutics

    BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the successful close of its acquisition of Mersana Therapeutics, Inc., (NASDAQ:MRSN) ("Mersana") following completion of all conditions of the tender offer to acquire all outstanding shares of Mersana at a price of $25 per share in cash, plus one non-tradable contingent value right ("CVR") per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash. "This acquisition of Mers

    1/6/26 9:02:10 AM ET
    $DAWN
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

    Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 millionClosing is expected to occur by the end of January 2026 CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter e

    11/14/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Biopharmaceuticals to Acquire Mersana Therapeutics

    Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million Closing is expected to occur by the end of January 2026 CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it has entered into a definitive merger agreement with Day One Biopharmaceuticals ("Day One"), pursua

    11/13/25 6:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    SEC Filings

    View All

    SEC Form 15-12G filed by Mersana Therapeutics Inc.

    15-12G - Mersana Therapeutics, Inc. (0001442836) (Filer)

    1/16/26 4:15:45 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Mersana Therapeutics Inc.

    EFFECT - Mersana Therapeutics, Inc. (0001442836) (Filer)

    1/9/26 12:15:03 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Mersana Therapeutics Inc.

    S-8 POS - Mersana Therapeutics, Inc. (0001442836) (Filer)

    1/6/26 4:19:14 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Financials

    Live finance-specific insights

    View All

    Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

    Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 millionClosing is expected to occur by the end of January 2026 CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter e

    11/14/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025

    CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2025 on Friday, November 14, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersa

    11/10/25 8:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

    More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2025. "During the second quarter, we were excited to

    8/13/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

    SC 13D/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/15/24 4:45:57 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

    SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/14/24 5:45:55 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

    SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/14/24 6:01:51 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Leadership Updates

    Live Leadership Updates

    View All

    Mersana Therapeutics Announces Changes in Leadership

    Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the

    9/6/23 7:00:40 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Provides Statement About SVB

    CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB. Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously

    3/10/23 7:10:38 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership

    CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's pri

    10/25/21 8:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care